<p>Celecoxib is absorbed rapidly in the gastrointestinal tract.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Gong L, Thorn CF, Bertagnolli MM, Grosser T, Altman RB, Klein TE: Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012 Apr;22(4):310-8. doi: 10.1097/FPC.0b013e32834f94cb. (PubMed ID 22336956)" href="#reference-A34124">7</a></sup> When a single oral dose of 200 mg was given to healthy research subjects, the peak plasma levels of celecoxib occurred within 3 hours.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Gong L, Thorn CF, Bertagnolli MM, Grosser T, Altman RB, Klein TE: Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012 Apr;22(4):310-8. doi: 10.1097/FPC.0b013e32834f94cb. (PubMed ID 22336956)" href="#reference-A34124">7</a>,<a class="reference-popover-link" data-content="FDA Approved Drug Products: CELEBREX (celecoxib) oral capsules" href="#reference-L7646">31</a></sup> The Cmax is 705 ng/mL.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Pfizer Medical Information" href="#reference-L3296">25</a></sup> When multiple doses are given, steady-state concentrations are reached on or before day 5. When taken with a high-fat meal, peak plasma levels are delayed for about 1 to 2 hours with an increase in total absorption (AUC) of 10% to 20%.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: CELEBREX (celecoxib) oral capsules" href="#reference-L7646">31</a></sup> The AUC of celecoxib has been shown to be significantly lower in patients with chronic renal impairment.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J: Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf. 2002;25(7):537-44. doi: 10.2165/00002018-200225070-00007. (PubMed ID 12093311)" href="#reference-A4983">12</a>,<a class="reference-popover-link" data-content="FDA Approved Drug Products: CELEBREX (celecoxib) oral capsules" href="#reference-L7646">31</a></sup> A meta-analysis of pharmacokinetic studies has suggested an approximately 40% higher AUC (area under the curve) of celecoxib in black patients compared to Caucasians for unknown reasons.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Pfizer Medical Information" href="#reference-L3296">25</a></sup></p>